Transfusion最新文献

{"title":"Assessing hepatitis B virus infectivity in blood components following pathogen reduction using a human hepatocyte model.","authors":"Bryan J Visser, Santanu Biswas, Rana Eltahan, Rafaelle Fares-Gusmao, Subramanian Yegneswaran, Nina Mufti, Carlos H Villa, David R McGivern","doi":"10.1111/trf.18357","DOIUrl":"https://doi.org/10.1111/trf.18357","url":null,"abstract":"<p><strong>Background: </strong>Pathogen reduction technologies (PRTs) have the potential to reduce the risk of emerging transfusion transmissible infections. Evaluating PRT activity against hepatitis B virus (HBV) presents some unique challenges due to the lack of robust model systems. Surrogate viruses (e.g., duck HBV) can be used, but may differ from the human pathogen in ways that influence susceptibility to a given PRT.</p><p><strong>Methods: </strong>Whole blood (WB) collected from volunteers was spiked with human plasma from deferred HBV-positive donors. Spiked WB was then treated with the nucleic acid crosslinking compound S-303 or left untreated. Additional physical and chemical treatments were also assessed. Plasma prepared from the spiked WB was used to inoculate human hepatocyte cultures isolated from chimeric mice with humanized livers. Culture medium was monitored over time for hepatitis B surface antigen (HBsAg) and viral DNA. Cell lysates were analyzed for evidence of covalently closed circular (ccc) DNA.</p><p><strong>Results: </strong>The culture system faithfully measured infectious HBV in blood components. S-303 treatment of HBV-spiked WB prevented infection of hepatocyte cultures, as monitored by HBsAg expression, at concentrations as low as 0.125 mM of S-303 or with incubation times as short as 1 h. Additionally, S-303 treatment prevented the accumulation of T5 exonuclease-resistant HBV DNA in inoculated hepatocytes, suggesting that S-303 prevents establishment of HBV cccDNA.</p><p><strong>Conclusion: </strong>This model mimics transfusion transmission by using donor-derived HBV and mouse-passaged human hepatocytes, allowing evaluation of the efficacy of different PRTs against authentic human HBV isolates. We found S-303 to be a potent inactivator of HBV.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare case of warm IgM autoimmune hemolytic anemia.","authors":"Bryan Tordon, Nour Alhomsi, Ali Iqbal, Azim Gangji, Gwen Clarke, Shuoyan Ning","doi":"10.1111/trf.18353","DOIUrl":"https://doi.org/10.1111/trf.18353","url":null,"abstract":"<p><p>Cold agglutinins are IgM-mediated autoimmune hemolytic processes that most often cause destruction of red blood cells at colder temperatures. Here we describe a case of a patient with history of living donor renal transplantation that developed an atypical autoantibody causing profound anemia and hemolysis which, although IgM in nature, reacted best at warmer temperatures and was caused by a lymphoproliferative disorder. The investigations and serological findings here raise awareness to less common forms of autoimmune hemolytic disorders and describe specialized tests that can help uncover these antibodies. This case also highlights a rare presentation of post-transplant lymphoproliferative disorder manifesting clinically as hemolytic anemia.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144708963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blood deserts in a universal health system: Addressing structural inequities in northern Canada.","authors":"Boaz Laor, Shreenik Kundu","doi":"10.1111/trf.18347","DOIUrl":"https://doi.org/10.1111/trf.18347","url":null,"abstract":"","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dose-dependent overestimation of IgM antibody titers by IgG in the column agglutination technique.","authors":"Hayato Kojima, Hideaki Matsuura, Yuko Abe, Ayuna Yamada, Yasuo Miura","doi":"10.1111/trf.18340","DOIUrl":"https://doi.org/10.1111/trf.18340","url":null,"abstract":"","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144668589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility and safety of peripheral blood stem cell collection in children with extremely low body weight: A single center study.","authors":"S Grewal, R Hassanein, S Mendoza, E Sajdak, H C Sullivan, R Jacob","doi":"10.1111/trf.18345","DOIUrl":"https://doi.org/10.1111/trf.18345","url":null,"abstract":"<p><strong>Background: </strong>Apheresis cell collections (HPC(A)) are used for hematopoietic stem cell transplantation and gene therapy; however, they present unique challenges in children with extremely low body weight (≤10 kg). We aimed to investigate the feasibility and safety of HPC(A) in these patients.</p><p><strong>Study design and methods: </strong>This retrospective single-center study reviewed HPC(A) collections at one pediatric center between 2017 and 2024 in patients ≤10 kg. Data included collection parameters, anticoagulant type, and demographics. Feasibility was assessed on target CD34+ count. Safety was evaluated on the incidence and severity of adverse events (AEs). Descriptive statistics and comparative tests (Wilcoxon rank sum, Welch t-test) were applied.</p><p><strong>Results: </strong>Nineteen patients underwent 20 autologous collections with an average patient weight of 7.70 kg. Central venous access was required in all, with 90% inpatient collections. Average patient total blood volume and volume processed were 557 and 2523 mL. Collections used acid citrate dextrose, solution A (ACD-A) only (50%) or ACD-A + heparin (50%). Run times between the two were not significantly different, but the inlet flow rate was significantly higher in the ACD-A + heparin group (p = .017). 90% of patients received granulocyte colony-stimulating factor only, with the remainder also receiving plerixafor. Average minimum-target dose was 12.8-20.5 million CD34/kg. The target dose was achieved on Day 1 of collection in 19 collections (95%), with the target achieved on Day 2 in the single remaining patient. There was one incidence of hypocalcemia with no serious AEs. Average collection efficiency (CE)1 and CE2 were 59% and 49%.</p><p><strong>Discussion: </strong>HPC(A) is feasible and safe in patients ≤10 kg, including with ACD-A + heparin anticoagulation, supporting broader application in this population.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current advances 2024: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies (AABB) Clinical Transfusion Medicine Committee.","authors":"Elizabeth P Crowe, Jennifer Andrews, Stella T Chou, Claudia S Cohn, Mischa L Covington, Ruchika Goel, Aaron S Hess, Tina S Ipe, Jessica Jacobson, Cyril Jacquot, Jenna Khan, Michael F Murphy, Kerry O'Brien, Monica B Pagano, Anil K Panigrahi, Jacqueline N Poston, Eric Salazar, Nabiha H Saifee, Moritz Stolla, Nicole D Zantek, Alyssa Ziman, Ryan A Metcalf","doi":"10.1111/trf.18330","DOIUrl":"https://doi.org/10.1111/trf.18330","url":null,"abstract":"","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One versus two: How much does it matter? A single-center retrospective study evaluating 1-day extracorporeal photopheresis schedule for treating patients with chronic lung allograft rejection.","authors":"Claudia Del Fante, Valentina Vertui, Catherine Klersy, Cristina Mortellaro, Domenica Federica Briganti, Letizia Corinna Morlacchi, Marianna Russo, Cesare Perotti, Federica Meloni","doi":"10.1111/trf.18318","DOIUrl":"https://doi.org/10.1111/trf.18318","url":null,"abstract":"<p><strong>Background: </strong>Several studies show that extracorporeal photopheresis (ECP) might benefit chronic lung allograft dysfunction (CLAD). A standard ECP cycle consists of two consecutive procedures regardless of the technique employed.</p><p><strong>Study design and methods: </strong>Evaluation of ECP cycle (from two to one procedure) modification due to pandemic restrictions in 25 patients with CLAD under chronic treatment by off-line ECP in the 6 months preceding cycle modification (one procedure processing 1.5 patients blood volumes [1.5 ECP]). Assessment of any significant change in lung function decline and the relationship with product characteristics compared to pre-ECP cycle modification.</p><p><strong>Results: </strong>ECP patients (23 obstructive and two mixed) were enrolled in 2020 during the COVID pandemic. Two hundred and thirty five ECP procedures followed the standard protocol and 121 the 1.5 ECP. There was little or no variation in lung function during the study period. The mean number of mononuclear cells (MNC) per kg administered over time was higher in the 1.5 ECP than in the standard ECP protocol (p = .014). No association was found between respiratory function and MNC infused. Persistent Forced Expiratory Volume in 1 s decline >10% was observed in two patients over the 6 months preceding 1.5 ECP (due to CLAD progression) and in three patients after 1.5 ECP initiation (one for CLAD progression, two for bronchial colonization).</p><p><strong>Conclusion: </strong>Our study shows that respiratory function is maintained over time and is comparable between both ECP strategies in responders. The shift from two to one procedure per cycle may be reasonable in CLAD patients treated by off-line ECP.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transfusion Camp for medical students in Rwanda: A multidisciplinary initiative teaching graduating medical students how to utilize blood products and derivatives safely in district hospitals.","authors":"McKenna Postles, Teresa Skelton, Jacob Pendergrast, Aggrey Dhabangi, Yulia Lin, Aimable Kanyamuhunga","doi":"10.1111/trf.18337","DOIUrl":"https://doi.org/10.1111/trf.18337","url":null,"abstract":"","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using geographic information system (GIS) technology to evaluate a hospital-based mobile blood donation program.","authors":"Kristen N Ruby, Walter H Dzik, Julia J Collins, Hongying Tang, Shawn Ela, Robert S Makar","doi":"10.1111/trf.18332","DOIUrl":"https://doi.org/10.1111/trf.18332","url":null,"abstract":"<p><strong>Background: </strong>Geographic information system (GIS) technology is widely used in public health to track disease patterns, though its application in transfusion medicine is limited. We report the use of GIS software by a hospital-based blood donor program to examine patterns of blood drive activity.</p><p><strong>Study design and methods: </strong>We performed a 3-year retrospective study examining our donor program's mobile drives. Esri ArcGIS Pro™ software and ArcGIS Online™ were used to create vector and choropleth maps reflecting activity by town.</p><p><strong>Results: </strong>Sixteen thousand nine mobile whole blood donations were identified in 2021-2023. Four hundred and fifty-five mobile blood drives were hosted at 189 unique locations. Seventeen towns within or intersecting a 15-mile radius of our donation center had never been visited by our bloodmobile during the study period, with adult population sizes ranging from approximately 3000 to 53,000 representing donation opportunities. Untapped blood mobile opportunities were also identified in 33 Massachusetts towns (>700,000 adults) with nearby healthcare facilities in our hospital network.</p><p><strong>Discussion: </strong>GIS-generated maps serve as an effective tool to identify previously successful blood donation locations and locations not yet visited by our donor program. Blood collection centers may benefit from future application of ArcGIS analysis tools to identify optimal locations for future mobile blood drives.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ABO-mismatched platelet and plasma transfusion practices and the potential for transfusion-related alpha-gal syndrome: The Biomedical Excellence for Safer Transfusion Collaborative Study.","authors":"Nancy M Dunbar, Richard M Kaufman, Karina S Bary, Gregory R M Bellairs, Claudia S Cohn, Fanny Delettre, Stephanie Ditcham, Gustavo C Duarte, Amanda Ellison, Roberta Fachini, Chloe E George, Catherine Humbrecht, Vernon Louw, Sascha Meier, Sarah Morley, Meridah Mwase, Nancy Robitaille, Kylie Rushford, Tomohiko Sato, Richard Schäfer, Julie Staves, Minoko Takanashi, Pierre Tiberghien, Silvano Wendel, Erica M Wood, Alyssa Ziman, Michael F Murphy","doi":"10.1111/trf.18338","DOIUrl":"https://doi.org/10.1111/trf.18338","url":null,"abstract":"<p><strong>Background: </strong>Alpha-gal syndrome (AGS) is caused by IgE antibodies against the alpha-gal oligosaccharide, which is structurally similar to the Group B antigen. Recent case reports of severe allergic transfusion reactions (ATRs) in Group O patients receiving Group B plasma and platelets raise the possibility of a new adverse event, herein called transfusion-related AGS (TRAGS). The primary goal of this study was to assess the frequency of Groups B and AB plasma and platelet transfusions to Group O patients.</p><p><strong>Study design and methods: </strong>In this multi-site retrospective study, participating sites submitted the numbers of platelet and plasma transfusions administered during a 2-year period categorized by patient and product ABO group.</p><p><strong>Results: </strong>Fourteen sites from 10 countries participated. Group O patients received Group AB for an average of 9.9% (range 2.8%-29.2%) of plasma transfusions and Group B for 3.2% (0%-12.8%). AB plasma transfusion to Group O patients represented 4.5% (0.9%-14.6%) of the total plasma transfused; Group B 1.4% (0%-5.1%). Group O patients received Group AB for an average of 1.5% (range 0%-5.9%) of platelet transfusions and Group B for 4.1% (0%-14.2%). AB platelet transfusion to Group O patients represented 0.6% (0%-2.7%) of the total platelets transfused; Group B platelets were 1.8% (0%-6.7%).</p><p><strong>Discussion: </strong>Evidence supporting the possibility of a new adverse event, TRAGS, is accumulating. This study quantifies how often Group O patients may be exposed to Group B antigen in Group B or AB plasma and/or platelet transfusions, providing an estimate of the scope of potential risk for TRAGS.</p>","PeriodicalId":23266,"journal":{"name":"Transfusion","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144609632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}